查看购物车
  • Traditional Chinese
  • English
  • Japanese
急性缺血性脑中风市场 - 全球及区域分析：按疗法和区域 - 分析与预测（2025-2035 年）
市场调查报告书
商品编码
1729049

急性缺血性脑中风市场 - 全球及区域分析：按疗法和区域 - 分析与预测（2025-2035 年）

Acute Ischemic Stroke Market - A Global and Regional Analysis: Focus on Therapeutics, and Regional Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

当供应大脑的血管被血栓阻塞时，就会发生急性缺血性脑中风，导致神经功能突然丧失。

这种阻塞会导致脑组织缺乏所需的氧气和营养，从而导致细胞死亡并可能造成长期损害。

全球急性缺血性脑中风市场的主要驱动因素之一是文明病的盛行率不断上升。高血压、糖尿病和肥胖等文明病会增加缺血性中风的风险。这导致对药物和治疗方法的需求增加。

儘管成长轨迹良好，但仍有若干挑战影响全球急性缺血性脑中风市场。主要挑战之一是在资源匮乏的环境中难以获得先进的医疗服务。然而，虽然 tPA 和血栓切除术等先进疗法正在改善治疗效果，但许多地区缺乏提供这些治疗所需的基础设施。这导致诊断和治疗的延迟，从而导致中风相关的残疾和死亡率显着增加。

全球急性缺血性脑中风市场也面临治疗费用上涨的问题。然而，机械血栓切除术、tPA 和中风后復健等最先进治疗的费用对于患者和医疗保健系统来说可能过高，尤其是在发展中地区。

每家公司都透过开发标靶治疗在推动缺血性中风治疗领域发展方面发挥关键作用。两家公司正在进行的研究和合作对于改善患者的治疗效果和扩大市场的治疗选择至关重要。

全球急性缺血性脑中风市场的竞争格局多种多样，不同地区的众多公司提供各种各样的产品。随着需求的不断增长，尤其是在亚太等新兴市场，预计区域参与企业和本地製造商将在市场成长中发挥关键作用。随着消费者偏好转向更谨慎、舒适和更实惠的治疗方法，急性缺血性脑中风市场预计将继续发展，为成熟公司和新兴企业创造新的机会。

总之，在医疗保健投资和研究不断增加的推动下，全球急性缺血性脑中风市场预计将持续成长。产品技术的不断进步和治疗选择的不断扩大将继续塑造市场的未来。随着急性缺血性脑中风市场需求的不断增长，全球和区域参与者都有望在满足个人和医疗保健系统的需求方面发挥关键作用。

本报告研究了全球急性缺血性脑中风市场，并概述了市场以及治疗剂、地区和公司概况的趋势。

目录

执行摘要

第一章全球急性缺血性脑中风市场：产业展望

  • 概述
  • 急性缺血性脑中风的监管现状
  • 急性缺血性脑中风市场及流行病学分析
  • 急性缺血性脑中风市场及专利模式
  • 急性缺血性脑中风市场和临床试验现状
  • 主要趋势
  • 市场动态

第 2 章。急性缺血性脑中风市场（按治疗剂，百万美元，2023-2035 年）

  • 溶栓治疗
  • 抗血小板治疗
  • 抗高血压治疗
  • 抗凝血剂

第 3 章。按地区分類的急性缺血性脑中风市场（百万美元，2023-2035 年）

  • 北美洲
  • 欧洲
  • 亚太地区

第四章 竞争格局与公司概况

  • 竞争格局
    • 新服务
    • 合併与收购
    • 伙伴关係、合作和业务扩展
    • 资金筹措活动
    • 监管部门核准
  • 公司简介
    • Acticor Biotech
    • Bristol-Myers Squibb
    • Genentech, Inc
    • Athersys|Healios KK
    • Biogen Inc
    • AbbVie
    • Revalesio Corporation
    • NoNO Inc.
    • Bayer
    • TrueBinding, Inc
    • Lumosa Therapeutics
    • Janssen Pharmaceutical
    • Silver Creek Pharmaceuticals

第五章调查方法

Product Code: BHL2880SA

Global Acute Ischemic Stroke Market, Analysis and Forecast: 2025-2035

An acute ischemic stroke occurs when a blood clot obstructs a blood vessel supplying blood to the brain, leading to a sudden loss of neurological function. This blockage deprives brain tissue of essential oxygen and nutrients, causing cell death and potential long-term disability.

One of the significant drivers of the global acute ischemic stroke market is the rising incidence of lifestyle disorders. The rising ages and lifestyle-related diseases such as hypertension, diabetes, and obesity which leads to increases the risk of ischemic stroke. This results in increasing demand of drug or therapies during the treatment.

Despite the positive growth trajectory, several challenges continue to impact the global acute ischemic stroke market. One of the primary challenges is limited access to advanced care in low-resource settings. However, the advanced treatments like tPA and thrombectomy have improved outcomes, many regions lack the necessary infrastructure to deliver these therapies. This results in underdiagnosis and delayed treatments, significantly increasing stroke-related disability and mortality.

The global acute ischemic stroke market is also facing high cost of treatment. However, the cost of cutting-edge treatments like mechanical thrombectomy, tPA, and post-stroke rehabilitation can be prohibitive for patients and healthcare systems, particularly in developing regions.

The companies play pivotal roles in advancing the treatment landscape for ischemic stroke through the development of targeted therapies. Their ongoing research and collaborations are essential in improving patient outcomes and expanding therapeutic options in this market.

The competitive landscape of the global acute ischemic stroke market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific. As consumer preferences shift towards more discreet, comfortable, and affordable therapies, the acute ischemic stroke market will continue to evolve, fostering new opportunities for both established and emerging companies.

Market Segmentation:

Segmentation 1: by Therapeutics

  • Thrombolytic Therapies
  • Antiplatelet Therapies
  • Antihypertensive Therapies
  • Anticoagulants

Segmentation 2: by Region

  • North America
  • Europe
  • Asia-Pacific

In conclusion, the global acute ischemic stroke market is on track for continued growth, driven by the growing healthcare investments and research. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for acute ischemic stroke market rises the therapies, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Key Questions Answered

Analysis and Forecast Note

1. Global Acute Ischemic Stroke Market: Industry Outlook

  • 1.1 Overview
  • 1.2 Regulatory Landscape of Acute Ischemic Stroke
  • 1.3 Acute Ischemic Stroke Market, Epidemiology Analysis
  • 1.4 Acute Ischemic Stroke Market, Patent Landscape
    • 1.4.1 By Country
    • 1.4.2 By Year
  • 1.5 Acute Ischemic Stroke Market, Clinical Trials Landscape
  • 1.6 Key Trends
  • 1.7 Market Dynamics
    • 1.7.1 Impact Analysis
    • 1.7.2 Market Drivers
    • 1.7.3 Market Restraints
    • 1.7.3 Market Opportunities

2. Global Acute Ischemic Stroke Market, By Therapeutics, $Million, 2023-2035

  • 2.1 Thrombolytic Therapies
  • 2.2 Antiplatelet Therapies
  • 2.3 Antihypertensive Therapies
  • 2.4 Anticoagulants

3. Global Acute Ischemic Stroke Market, by Region, $Million, 2023-2035

  • 3.1 North America
    • 3.1.1 Key Findings in North America
    • 3.1.2 Business Drivers
    • 3.1.3 Business Challenges
    • 3.1.4 Market Sizing and Forecast
      • 3.1.4.1 North America Acute Ischemic Stroke Market, By Country
        • 3.1.4.1.1 U.S.
  • 3.2 Europe
    • 3.2.1 Key Findings in Europe
    • 3.2.2 Business Drivers
    • 3.2.3 Business Challenges
    • 3.2.4 Market Sizing and Forecast
      • 3.2.4.1 Europe Acute Ischemic Stroke Market, By Country
        • 3.2.4.1.1 Germany
        • 3.2.4.1.2 U.K.
        • 3.2.4.1.3 France
        • 3.2.4.1.4 Italy
        • 3.2.4.1.5 Spain
  • 3.3 Asia-Pacific
    • 3.3.1 Key Findings in Asia-Pacific
    • 3.3.2 Business Drivers
    • 3.3.3 Business Challenges
    • 3.3.4 Market Sizing and Forecast
      • 3.3.4.1 Asia-Pacific Acute Ischemic Stroke Market, By Country
        • 3.3.4.1.1 Japan

4. Competitive Landscape and Company Profiles

  • 4.1 Competitive Landscape
    • 4.1.1 New Offerings
    • 4.1.2 Mergers and Acquisitions
    • 4.1.3 Partnerships, Alliances, and Business Expansion
    • 4.1.4 Funding Activities
    • 4.1.5 Regulatory Approvals
  • 4.2 Company Profile
    • 4.2.1 Acticor Biotech
      • 4.2.1.1 Overview
      • 4.2.1.2 Product Portfolio
      • 4.2.1.3 Target Customers
      • 4.2.1.4 Key Professionals
      • 4.2.1.5 Analyst View
    • 4.2.2 Bristol-Myers Squibb
      • 4.2.2.1 Overview
      • 4.2.2.2 Product Portfolio
      • 4.2.2.3 Target Customers
      • 4.2.2.4 Key Professionals
      • 4.2.2.5 Analyst View
    • 4.2.3 Genentech, Inc
      • 4.2.3.1 Overview
      • 4.2.3.2 Product Portfolio
      • 4.2.3.3 Target Customers
      • 4.2.3.4 Key Professionals
      • 4.2.3.5 Analyst View
    • 4.2.4 Athersys|Healios K.K.
      • 4.2.3.1 Overview
      • 4.2.3.2 Product Portfolio
      • 4.2.3.3 Target Customers
      • 4.2.3.4 Key Professionals
      • 4.2.3.5 Analyst View
    • 4.2.5 Biogen Inc
      • 4.2.5.1 Overview
      • 4.2.5.2 Product Portfolio
      • 4.2.5.3 Target Customers
      • 4.2.5.4 Key Professionals
      • 4.2.5.5 Analyst View
    • 4.2.6 AbbVie
      • 4.2.6.1 Overview
      • 4.2.6.2 Product Portfolio
      • 4.2.6.3 Target Customers
      • 4.2.6.4 Key Professionals
      • 4.2.6.5 Analyst View
    • 4.2.7 Revalesio Corporation
      • 4.2.7.1 Overview
      • 4.2.7.2 Product Portfolio
      • 4.2.7.3 Target Customers
      • 4.2.7.4 Key Professionals
      • 4.2.7.5 Analyst View
    • 4.2.8 NoNO Inc.
      • 4.2.8.1 Overview
      • 4.2.8.2 Product Portfolio
      • 4.2.8.3 Target Customers
      • 4.2.8.4 Key Professionals
      • 4.2.8.5 Analyst View
    • 4.2.9 Bayer
      • 4.2.9.1 Overview
      • 4.2.9.2 Product Portfolio
      • 4.2.9.3 Target Customers
      • 4.2.9.4 Key Professionals
      • 4.2.9.5 Analyst View
    • 4.2.10 TrueBinding, Inc
      • 4.2.10.1 Overview
      • 4.2.10.2 Product Portfolio
      • 4.2.10.3 Target Customers
      • 4.2.10.4 Key Professionals
      • 4.2.10.5 Analyst View
    • 4.2.11 Lumosa Therapeutics
      • 4.2.11.1 Overview
      • 4.2.11.2 Product Portfolio
      • 4.2.11.3 Target Customers
      • 4.2.11.4 Key Professionals
      • 4.2.11.5 Analyst View
    • 4.1.12 Janssen Pharmaceutical
      • 4.2.12.1 Overview
      • 4.2.12.2 Product Portfolio
      • 4.2.12.3 Target Customers
      • 4.2.12.4 Key Professionals
      • 4.2.12.5 Analyst View
    • 4.2.13 Silver Creek Pharmaceuticals
      • 4.2.13.1 Overview
      • 4.2.13.2 Product Portfolio
      • 4.2.13.3 Target Customers
      • 4.2.13.4 Key Professionals
      • 4.2.13.5 Analyst View

5. Research Methodology

List of Figures

  • Figure: Global Acute Ischemic Stroke Market (by Region), $Million, 2024 and 2035
  • Figure: Global Acute Ischemic Stroke Market Coverage
  • Figure: Global Acute Ischemic Stroke Market Key Trends, Impact Analysis, 2024-2035

List of Tables

  • Table: Global Acute Ischemic Stroke Market, Patent Analysis, January 2022-March 2025
  • Table: Global Acute Ischemic Stroke Market Dynamics, Impact Analysis
  • Table: Global Acute Ischemic Stroke Market (by Therapeutics), $Million, 2023-2035
  • Table: Global Acute Ischemic Stroke Market (by Region), $Million, 2023-2035